Below you will find a list of upcoming CCSN webinars, along with further information and registration links where applicable.
Keep watching this page for new webinars, and register in advance to save the date in your calendar!
NOTE: If you wish to see a webinar but may not be able to attend live, registering for the webinar guarantees that a recording of the webinar will be sent to your inbox the day after the webinar livecast.
Date: May 27th, 2021
Presented by: Dr. Poul Sorensen, MD, PhD, FRCPC; Dr. Muhammad Zulfiqar, MD; Ted Taylor, Patient Advocate
Twenty years ago, Dr. Poul Sorensen discovered a gene mutation in a rare paediatric cancer, which has led to the development of a new drug that can target a variety of tumour types that originate in different parts of the body . This cancer type, known as TRK fusion cancer, occurs when the over-expression of a TRK fusion protein results in the growth of a tumour. Larotrectinib (Vitravki®) is an example of a tumour agnostic treatment, which targets tumours not according to their location in the body, but by targeting a certain property of the tumour cells, called a biomarker.
In this webinar, we will hear from Dr. Sorensen about his groundbreaking discovery and how it contributed to the development of tumour agnostic treatments. Dr. Zulfiqar, a medical oncologist at the BC Cancer Agency, will further discuss TRK fusion cancers and how he has been able to treat patients. Lastly, we will hear from Ted Taylor, a TRK fusion cancer patient diagnosed with glioblastoma (GBM) multiform being treated with Vitrakvi.